PP
NEOS

PDT Partners’s Neos Therapeutics, Inc NEOS Stock Holding History

PDT Partners’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-15,500
Closed -$144K – 527
2016
Q2 		$144K Buy
15,500
+200
+1% +$1.91K 0.01% 418
2016
Q1 		$165K Buy
+15,300
New +$161K 0.01% 521

Other funds holding NEOS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

PDT Partners's NEOS Position: Q3 2016 in Review

PDT Partners sold out of Neos Therapeutics, Inc (NEOS) in Q3 2016, closing a stake of 15,500 shares — an estimated $144K sold.

PDT Partners first reported a position in NEOS in Q1 2016 and held it in 2 quarters. The position peaked at $165K in Q1 2016. 48 funds tracked by Wall St. Rank hold NEOS as of Q3 2016.

  • PDT Partners reported no remaining Neos Therapeutics, Inc position as of Q3 2016 after selling out during the quarter.
  • PDT Partners sold 15,500 Neos Therapeutics, Inc shares in Q3 2016, an estimated $144K.
  • PDT Partners first reported a position in Neos Therapeutics, Inc in Q1 2016 and held it in 2 quarters.
  • PDT Partners's Neos Therapeutics, Inc position peaked at $165K in Q1 2016.
  • 48 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q3 2016.

Based on PDT Partners's 13F filing for Q3 2016, filed 14 Nov 2016.